A Bruton's tyrosine kinase inhibitor  reduces BA synthesis by activating FXR and downregulating CYP7A1 expression, thereby ameliorating hepatic lipid metabolism and inflammation in MASLD [169]. This evidence concerns the gene CYP7A1 and metabolic dysfunction-associated steatotic liver disease.